Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU-a randomized controlled trial
- PMID: 23361033
- DOI: 10.1097/CCM.0b013e31826a409c
Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU-a randomized controlled trial
Abstract
Objective: To evaluate the efficacy of probiotics in prevention of Candida colonization in a PICU.
Design: Prospective double blinded, randomized controlled trial.
Setting: PICU of a tertiary care teaching hospital in north India.
Subjects: One hundred fifty children (106 boys, 44 girls), 3 months to 12 yrs old, on broad spectrum antibiotics for at least 48 hrs were randomized using computer-generated random numbers to receive probiotic mix (EUGI) (n = 75) or placebo (n = 75).
Intervention: Patients received one sachet twice a day of either probiotics or placebo for 7 days. Probiotics contained Lactobacillus acidophillus, Lactobacillus rhamnosum, Bifidobacterium longum, Bifidobacterium bifidum, Saccharomyces boulardi, Saccharomyces thermophilus, fructo-oligosaccharides; and placebo-contained lactose packed in similar-looking sachets. Rectal swabs for fungal culture were taken at day 0, 7, and 14 of enrollment. Primary outcome measure was prevalence of rectal colonization with Candida on day 14 postenrollment; secondary outcomes were growth of Candida in urine (candiduria) and blood (candidemia). Patients were followed until completion of 14 days study period or death of patient.
Results: Demographic and clinical variables were comparable in two groups. Prevalence of Candida colonization on day 0 was similar (15 of 75) in both the groups. On day 7, 27.9% (19 of 68) patients in the probiotic group and 42.6% (29 of 68) patients in the placebo group were colonized (relative risk 0.65; 95% confidence interval 0.41-1.05; p = 0.07), whereas, on day 14, colonization was observed in 31.3% (21 of 67) patients in the probiotic group and 50% (34 of 68) in the placebo group (relative risk 0.63; 95% confidence interval 0.41-0.96; p = 0.02). Thus, the relative reduction in prevalence of Candida colonization on day 7 and 14 in the probiotic group was 34.5% and 37.2%, respectively. The increase in number of colonized patients from day 0 to 7 and day 0 to 14 was significant in the placebo group (p = 0.004 and 0.001, respectively) but not in the probiotic group (p = 0.30 and 0.19, respectively; McNemar test). Candiduria was significantly less common in the probiotic group than in the placebo group (17.3% vs. 37.3%; relative risk 0.46; 95% confidence interval 0.26-0.82; p = 0.006). However, prevalence of candidemia did not differ significantly in two groups (1.6% in the probiotic group vs. 6.35% in placebo group; relative risk 0.46; 95% confidence interval 0.08-2.74; p = 0.39).
Conclusions: Supplementation with probiotics could be a potential strategy to reduce gastrointestinal Candida colonization and candiduria in critically ill children receiving broad spectrum antibiotics.
Comment in
-
Preventing invasive candidiasis in high-risk critically ill patients: avoid antibiotics or give probiotics?Crit Care Med. 2013 Feb;41(2):689-90. doi: 10.1097/CCM.0b013e3182741beb. Crit Care Med. 2013. PMID: 23353962 No abstract available.
Similar articles
-
Probiotic use and prevalence of candidemia and candiduria in a PICU.Pediatr Crit Care Med. 2013 Nov;14(9):e409-15. doi: 10.1097/PCC.0b013e31829f5d88. Pediatr Crit Care Med. 2013. PMID: 23965638
-
Candida colonization and candidemia in a pediatric intensive care unit.Pediatr Crit Care Med. 2008 Jan;9(1):91-5. doi: 10.1097/01.PCC.0000298643.48547.83. Pediatr Crit Care Med. 2008. PMID: 18477920
-
A multicenter, randomized trial of prophylactic fluconazole in preterm neonates.N Engl J Med. 2007 Jun 14;356(24):2483-95. doi: 10.1056/NEJMoa065733. N Engl J Med. 2007. PMID: 17568029 Clinical Trial.
-
Probiotics for prevention and treatment of diarrhea.J Clin Gastroenterol. 2011 Nov;45 Suppl:S149-53. doi: 10.1097/MCG.0b013e3182257e98. J Clin Gastroenterol. 2011. PMID: 21992955 Review.
-
Role of probiotics in prevention of Candida infection in critically ill children.Mycoses. 2013 May;56(3):204-11. doi: 10.1111/myc.12021. Epub 2012 Nov 26. Mycoses. 2013. PMID: 23176162 Review.
Cited by
-
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.Heliyon. 2024 Mar 2;10(5):e27239. doi: 10.1016/j.heliyon.2024.e27239. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463778 Free PMC article. Review.
-
Bifidobacteria in disease: from head to toe.Folia Microbiol (Praha). 2024 Feb;69(1):1-15. doi: 10.1007/s12223-023-01087-3. Folia Microbiol (Praha). 2024. PMID: 37644256 Review.
-
An Overview of the Public Health Challenges in Diagnosing and Controlling Human Foodborne Pathogens.Vaccines (Basel). 2023 Mar 24;11(4):725. doi: 10.3390/vaccines11040725. Vaccines (Basel). 2023. PMID: 37112637 Free PMC article. Review.
-
The potential role of adherence factors in probiotic function in the gastrointestinal tract of adults and pediatrics: a narrative review of experimental and human studies.Gut Microbes. 2022 Jan-Dec;14(1):2149214. doi: 10.1080/19490976.2022.2149214. Gut Microbes. 2022. PMID: 36469568 Free PMC article. Review.
-
What Is Candida Doing in My Food? A Review and Safety Alert on Its Use as Starter Cultures in Fermented Foods.Microorganisms. 2022 Sep 16;10(9):1855. doi: 10.3390/microorganisms10091855. Microorganisms. 2022. PMID: 36144457 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
